{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2FRefractory+Lymphomas&page=9",
    "query": {
      "condition": "Relapsed/Refractory Lymphomas",
      "page": 9
    },
    "page_size": 10
  },
  "pagination": {
    "page": 9,
    "page_size": 10,
    "total_count": 1803,
    "total_pages": 181,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2FRefractory+Lymphomas&page=10&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2FRefractory+Lymphomas&page=8&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-12T03:59:03.118Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01874054",
      "title": "Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hodgkin Disease"
      ],
      "interventions": [
        {
          "name": "brentuximab vedotin",
          "type": "DRUG"
        },
        {
          "name": "bendamustine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Seagen Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 55,
      "start_date": "2013-06",
      "completion_date": "2018-02-20",
      "has_results": true,
      "last_update_posted_date": "2019-02-12",
      "last_synced_at": "2026-11-12T03:59:03.118Z",
      "location_count": 13,
      "location_summary": "Birmingham, Alabama • San Francisco, California • Stanford, California + 10 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Whittier",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01874054"
    },
    {
      "nct_id": "NCT02879695",
      "title": "Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent B Acute Lymphoblastic Leukemia",
        "Recurrent Mixed Phenotype Acute Leukemia",
        "Refractory B Acute Lymphoblastic Leukemia",
        "Refractory Mixed Phenotype Acute Leukemia"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Blinatumomab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Bone Marrow Aspiration and Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2017-10-25",
      "completion_date": "2027-07-18",
      "has_results": true,
      "last_update_posted_date": "2026-08-20",
      "last_synced_at": "2026-11-12T03:59:03.118Z",
      "location_count": 7,
      "location_summary": "New Haven, Connecticut • Lexington, Kentucky • Baltimore, Maryland + 4 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02879695"
    },
    {
      "nct_id": "NCT01239875",
      "title": "Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Cutaneous B-cell Non-Hodgkin Lymphoma",
        "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue",
        "Nodal Marginal Zone B-cell Lymphoma",
        "Adult Diffuse Mixed Cell Lymphoma",
        "Adult Diffuse Small Cleaved Cell Lymphoma",
        "Adult Grade III Lymphomatoid Granulomatosis",
        "Adult Immunoblastic Large Cell Lymphoma",
        "Adult Lymphoblastic Lymphoma",
        "Grade 1 Follicular Lymphoma",
        "Grade 2 Follicular Lymphoma",
        "Grade 3 Follicular Lymphoma",
        "Mantle Cell Lymphoma",
        "Marginal Zone Lymphoma",
        "Small Lymphocytic Lymphoma",
        "Splenic Marginal Zone Lymphoma",
        "Waldenstrom Macroglobulinemia With Nodal Disease"
      ],
      "interventions": [
        {
          "name": "dendritic cell vaccine therapy",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cryotherapy",
          "type": "PROCEDURE"
        },
        {
          "name": "pneumococcal polyvalent vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "immunoenzyme technique",
          "type": "OTHER"
        },
        {
          "name": "immunohistochemistry staining method",
          "type": "OTHER"
        },
        {
          "name": "autologous dendritic cell-tumor fusion vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 16,
      "start_date": "2010-11",
      "completion_date": "2019-07-17",
      "has_results": false,
      "last_update_posted_date": "2020-01-14",
      "last_synced_at": "2026-11-12T03:59:03.118Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01239875"
    },
    {
      "nct_id": "NCT04323657",
      "title": "TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non Hodgkin Lymphoma",
        "Acute Lymphoblastic Leukemia",
        "Diffuse Large B Cell Lymphoma",
        "Primary Mediastinal Large B Cell Lymphoma",
        "Mantle Cell Lymphoma",
        "Follicular Lymphoma"
      ],
      "interventions": [
        {
          "name": "TC-110 T Cells",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "TCR2 Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2020-03-27",
      "completion_date": "2023-02-24",
      "has_results": false,
      "last_update_posted_date": "2023-03-16",
      "last_synced_at": "2026-11-12T03:59:03.118Z",
      "location_count": 3,
      "location_summary": "Denver, Colorado • Nashville, Tennessee • Houston, Texas",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04323657"
    },
    {
      "nct_id": "NCT04939272",
      "title": "Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Mantle Cell Lymphoma",
        "Refractory Mantle Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Copanlisib Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2022-06-29",
      "completion_date": "2027-02-12",
      "has_results": false,
      "last_update_posted_date": "2026-04-20",
      "last_synced_at": "2026-11-12T03:59:03.118Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04939272"
    },
    {
      "nct_id": "NCT00068302",
      "title": "Sirolimus in Treating Young Patients With Relapsed or Refractory Acute Leukemia or Non-Hodgkin's Lymphoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leukemia",
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "sirolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Children's Hospital of Philadelphia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 10,
      "start_date": "2003-01",
      "completion_date": "2013-07",
      "has_results": false,
      "last_update_posted_date": "2015-03-12",
      "last_synced_at": "2026-11-12T03:59:03.118Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00068302"
    },
    {
      "nct_id": "NCT01217229",
      "title": "Safety and Efficacy Study of PLX3397 in Adults With Relapsed or Refractory Hodgkin Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "PLX3397",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daiichi Sankyo",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2011-03-03",
      "completion_date": "2012-04-26",
      "has_results": true,
      "last_update_posted_date": "2020-06-30",
      "last_synced_at": "2026-11-12T03:59:03.118Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • Chicago, Illinois • Rochester, Minnesota + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01217229"
    },
    {
      "nct_id": "NCT07257419",
      "title": "CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Relapsed Pediatric ALL",
        "Hematopoietic Cell Transplantation",
        "Hematologic Malignancy"
      ],
      "interventions": [
        {
          "name": "Anti-Thymocyte Globulin (Rabbit)",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Thiotepa",
          "type": "DRUG"
        },
        {
          "name": "Mesna",
          "type": "DRUG"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Filgrastim",
          "type": "DRUG"
        },
        {
          "name": "CliniMACS System",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "St. Jude Children's Research Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 70,
      "start_date": "2026-10-03",
      "completion_date": "2035-12",
      "has_results": false,
      "last_update_posted_date": "2026-08-28",
      "last_synced_at": "2026-11-12T03:59:03.118Z",
      "location_count": 1,
      "location_summary": "Memphis, Tennessee",
      "locations": [
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07257419"
    },
    {
      "nct_id": "NCT04223765",
      "title": "Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Mantle Cell Lymphoma",
        "Follicular Lymphoma",
        "Splenic Marginal Zone Lymphoma",
        "Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue",
        "Nodal Marginal Zone Lymphoma",
        "Indolent Non-hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "CAR.k.28",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Bendamustine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UNC Lineberger Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2020-11-12",
      "completion_date": "2043-03-22",
      "has_results": false,
      "last_update_posted_date": "2026-01-20",
      "last_synced_at": "2026-11-12T03:59:03.118Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04223765"
    },
    {
      "nct_id": "NCT00053963",
      "title": "FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Blastic Phase Chronic Myelogenous Leukemia",
        "Childhood Central Nervous System Germ Cell Tumor",
        "Childhood Choroid Plexus Tumor",
        "Childhood Chronic Myelogenous Leukemia",
        "Childhood Craniopharyngioma",
        "Childhood Grade I Meningioma",
        "Childhood Grade II Meningioma",
        "Childhood Grade III Meningioma",
        "Childhood High-grade Cerebral Astrocytoma",
        "Childhood Infratentorial Ependymoma",
        "Childhood Low-grade Cerebral Astrocytoma",
        "Childhood Spinal Cord Neoplasm",
        "Childhood Supratentorial Ependymoma",
        "Recurrent Childhood Acute Lymphoblastic Leukemia",
        "Recurrent Childhood Acute Myeloid Leukemia",
        "Recurrent Childhood Brain Stem Glioma",
        "Recurrent Childhood Cerebellar Astrocytoma",
        "Recurrent Childhood Cerebral Astrocytoma",
        "Recurrent Childhood Ependymoma",
        "Recurrent Childhood Medulloblastoma",
        "Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor",
        "Recurrent Childhood Visual Pathway and Hypothalamic Glioma",
        "Refractory Chronic Lymphocytic Leukemia",
        "Relapsing Chronic Myelogenous Leukemia",
        "Unspecified Childhood Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "romidepsin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 30,
      "start_date": "2002-09",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-01-16",
      "last_synced_at": "2026-11-12T03:59:03.118Z",
      "location_count": 1,
      "location_summary": "Arcadia, California",
      "locations": [
        {
          "city": "Arcadia",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00053963"
    }
  ]
}